Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A E Dear

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
European Journal of Biochemistry|April 2, 1998
The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic moleculeA E Dear, R L Medcalf
Biochimica Et Biophysica Acta|September 27, 2000
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activityA E Dear, R L Medcalf
FEBS Letters|February 3, 1997
Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 cells utilises AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNAA E Dear, M Costa, R L Medcalf
Pathology|January 1, 1996
Malignant pulmonary lymphoid disease: case reports illustrating anatomical pattern of disease as a prognostic markerA E Dear, D Goldstein, J A Hayman
Internal Medicine Journal|October 6, 2012
Clinical-scientific notesR J Dick, K A Byron, A E Dear
European Journal of Biochemistry|October 1, 1996
Molecular mechanisms governing tumor-necrosis-factor-mediated regulation of plasminogen-activator inhibitor type-2 gene expressionA E Dear, Y Shen, M Rüegg, et al.
International Journal of Oncology|July 23, 2014
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignanciesH B Liu, D Urbanavicius, P Tan, et al.
International Journal of Oncology|January 22, 2011
The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidineH B Liu, P A Mayes, P Perlmutter, et al.
Biochemical and Biophysical Research Communications|July 2, 2005
Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activationH B Liu, Y S Hu, R L Medcalf, et al.
International Journal of Oncology|January 17, 2009
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expressionH B Liu, M T Voso, D Gumiero, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
European Journal of Biochemistry|April 2, 1998
The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic moleculeA E Dear, R L Medcalf
Biochimica Et Biophysica Acta|September 27, 2000
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activityA E Dear, R L Medcalf
FEBS Letters|February 3, 1997
Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 cells utilises AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNAA E Dear, M Costa, R L Medcalf
Pathology|January 1, 1996
Malignant pulmonary lymphoid disease: case reports illustrating anatomical pattern of disease as a prognostic markerA E Dear, D Goldstein, J A Hayman
Internal Medicine Journal|October 6, 2012
Clinical-scientific notesR J Dick, K A Byron, A E Dear
European Journal of Biochemistry|October 1, 1996
Molecular mechanisms governing tumor-necrosis-factor-mediated regulation of plasminogen-activator inhibitor type-2 gene expressionA E Dear, Y Shen, M Rüegg, et al.
International Journal of Oncology|July 23, 2014
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignanciesH B Liu, D Urbanavicius, P Tan, et al.
International Journal of Oncology|January 22, 2011
The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidineH B Liu, P A Mayes, P Perlmutter, et al.
Biochemical and Biophysical Research Communications|July 2, 2005
Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activationH B Liu, Y S Hu, R L Medcalf, et al.
International Journal of Oncology|January 17, 2009
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expressionH B Liu, M T Voso, D Gumiero, et al.
Pageof 2